Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
GENE's Cash to Debt is ranked higher than
76% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. GENE: N/A )
Ranked among companies with meaningful Cash to Debt only.
GENE' s Cash to Debt Range Over the Past 10 Years
Min: 0.85  Med: 28.97 Max: No Debt
Current: N/A
Equity to Asset 0.92
GENE's Equity to Asset is ranked higher than
95% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. GENE: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
GENE' s Equity to Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.79 Max: 0.92
Current: 0.92
0.09
0.92
F-Score: 3
Z-Score: 5.27
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -278.62
GENE's Operating margin (%) is ranked lower than
80% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. GENE: -278.62 )
Ranked among companies with meaningful Operating margin (%) only.
GENE' s Operating margin (%) Range Over the Past 10 Years
Min: -278.71  Med: -69.11 Max: 5.29
Current: -278.62
-278.71
5.29
Net-margin (%) -289.80
GENE's Net-margin (%) is ranked lower than
82% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. GENE: -289.80 )
Ranked among companies with meaningful Net-margin (%) only.
GENE' s Net-margin (%) Range Over the Past 10 Years
Min: -289.9  Med: -61.78 Max: 4.98
Current: -289.8
-289.9
4.98
ROE (%) -167.09
GENE's ROE (%) is ranked lower than
91% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. GENE: -167.09 )
Ranked among companies with meaningful ROE (%) only.
GENE' s ROE (%) Range Over the Past 10 Years
Min: -271.23  Med: -48.01 Max: 14.99
Current: -167.09
-271.23
14.99
ROA (%) -114.04
GENE's ROA (%) is ranked lower than
92% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. GENE: -114.04 )
Ranked among companies with meaningful ROA (%) only.
GENE' s ROA (%) Range Over the Past 10 Years
Min: -134.56  Med: -39.49 Max: 10.58
Current: -114.04
-134.56
10.58
ROC (Joel Greenblatt) (%) -3439.03
GENE's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. GENE: -3439.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GENE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2298.65  Med: -373.25 Max: 67.19
Current: -3439.03
-2298.65
67.19
Revenue Growth (3Y)(%) -100.00
GENE's Revenue Growth (3Y)(%) is ranked lower than
97% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. GENE: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GENE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 58.7
Current: -100
0
58.7
EPS Growth (3Y)(%) -10.10
GENE's EPS Growth (3Y)(%) is ranked lower than
65% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. GENE: -10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GENE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -7.90 Max: 71
Current: -10.1
0
71
» GENE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

GENE Guru Trades in Q4 2014

Jim Simons 294,000 sh (+170.22%)
» More
Q1 2015

GENE Guru Trades in Q1 2015

Jim Simons 650,780 sh (+1006.77%)
» More
Q2 2015

GENE Guru Trades in Q2 2015

Jim Simons 610,780 sh (-6.15%)
» More
Q3 2015

GENE Guru Trades in Q3 2015

Jim Simons 383,780 sh (-37.17%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.94
GENE's P/B is ranked higher than
66% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. GENE: 1.94 )
Ranked among companies with meaningful P/B only.
GENE' s P/B Range Over the Past 10 Years
Min: 0.67  Med: 4.00 Max: 26
Current: 1.94
0.67
26
P/S 6.81
GENE's P/S is ranked lower than
99.99% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. GENE: 6.81 )
Ranked among companies with meaningful P/S only.
GENE' s P/S Range Over the Past 10 Years
Min: 0  Med: 3.20 Max: 19.33
Current: 6.81
0
19.33
Days Inventory 54.28
GENE's Days Inventory is ranked higher than
65% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. GENE: 54.28 )
Ranked among companies with meaningful Days Inventory only.
GENE' s Days Inventory Range Over the Past 10 Years
Min: 21.15  Med: 64.86 Max: 108.56
Current: 54.28
21.15
108.56
Days Sales Outstanding 63.03
GENE's Days Sales Outstanding is ranked higher than
55% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. GENE: 63.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
GENE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.43  Med: 32.80 Max: 63.06
Current: 63.03
12.43
63.06
Days Payable 211.79
GENE's Days Payable is ranked higher than
87% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. GENE: 211.79 )
Ranked among companies with meaningful Days Payable only.
GENE' s Days Payable Range Over the Past 10 Years
Min: 63.84  Med: 169.67 Max: 357.55
Current: 211.79
63.84
357.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.28
GENE's Price/Net Cash is ranked lower than
99.99% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.08 vs. GENE: 1.28 )
Ranked among companies with meaningful Price/Net Cash only.
GENE' s Price/Net Cash Range Over the Past 10 Years
Min: 2.5  Med: 7.50 Max: 50
Current: 1.28
2.5
50
Price/Net Current Asset Value 1.28
GENE's Price/Net Current Asset Value is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. GENE: 1.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GENE' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.5  Med: 6.00 Max: 50
Current: 1.28
1.5
50
Price/Tangible Book 1.28
GENE's Price/Tangible Book is ranked higher than
74% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. GENE: 1.28 )
Ranked among companies with meaningful Price/Tangible Book only.
GENE' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.5  Med: 4.50 Max: 25
Current: 1.28
1.5
25
Earnings Yield (Greenblatt) (%) -31.30
GENE's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. GENE: -31.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GENE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -31.3  Med: 2.10 Max: 3.6
Current: -31.3
-31.3
3.6

More Statistics

Revenue(Mil) $2
EPS $ -0.95
Beta2.08
Short Percentage of Float6.95%
52-Week Range $1.62 - 11.00
Shares Outstanding(Mil)11.44

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:GTG.Australia, DU8.Germany, GNTLF.USA,
Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.
» More Articles for GENE

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
5:16 am Genetic Technologies executes a Settlement and Release Agreement with Hendrix Genetics B.V. Feb 07 2016
The Top 5 Penny Stocks for 2016 (CRIS, AG) Jan 04 2016
What Stands Behind These Stocks’ Bullish Moves Today? Dec 21 2015
4 Stocks Trading With Heavy Volume Today Dec 21 2015
Genetic Technologies Announces Publication of Key Scientific Validation Results in Support of... Dec 21 2015
GENETIC TECHNOLOGIES LTD Financials Dec 08 2015
4 Stocks Heading Into Thanksgiving On A High Note Nov 25 2015
Biotech Sector Due Diligence Report Highlights 4 Emerging Companies - Broad Street Alerts Nov 24 2015
Why US manufacturers are taking jobs to China Sep 21 2015
Genetic Technologies Granted Key Patents by US Patent Office for BREVAGenplus(R) Aug 06 2015
Genetic Technologies Announces Scientific Validation, Clinical Trial and Peer Review Publication... Jul 14 2015
Genetic Technologies Announces Appointment of Chief Financial Officer Jun 15 2015
Genetic Technologies Drives Ahead in the Fight Against Cancer Apr 20 2015
Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test Apr 20 2015
Genetic Technologies Announces: Additional Breast Health Centres to Begin Offering BREVAGenplus(R) Apr 20 2015
These 5 Stocks Have More Than Doubled In 2015 Apr 06 2015
Genetic Technologies Appoints Eutillio Buccilli as Chief Executive Officer Feb 26 2015
The Trade Traders are Waiting for in Genetic Technologies ($GENE) Feb 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK